Share on StockTwits
 

Ocera Therapeutics (NASDAQ:OCRX) was downgraded by Zacks to a “neutral” rating in a research note issued to investors on Wednesday, AnalystRatings.Net reports. They currently have a $13.60 price objective on the stock. Zacks‘ price objective points to a potential upside of 4.70% from the company’s current price.

OCRX has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus initiated coverage on shares of Ocera Therapeutics in a research note to investors on Monday. They set a “buy” rating and a $19.00 price target on the stock. Analysts at Cowen and Company initiated coverage on shares of Ocera Therapeutics in a research note to investors on Tuesday, December 17th. They set an “outperform” rating on the stock.

Ocera Therapeutics (NASDAQ:OCRX) traded up 4.76% during mid-day trading on Wednesday, hitting $12.99. The stock had a trading volume of 42,344 shares. Ocera Therapeutics has a 1-year low of $2.00 and a 1-year high of $17.50. The stock has a 50-day moving average of $10.53 and a 200-day moving average of $8.50. The company’s market cap is $198.1 million.

Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.77) EPS for the quarter. Analysts expect that Ocera Therapeutics will post $-2.55 EPS for the current fiscal year.

Ocera Therapeutics, Inc, formerly Tranzyme, Inc, is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (NASDAQ:OCRX) motility disorders.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.